Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
30.16
-0.97 (-3.12%)
Jun 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.14 - 31.23
52 week 17.95 - 31.24
Open 31.06
Vol / Avg. 398,371.00/498,915.00
Mkt cap 1.61B
P/E     -
Div/yield     -
EPS -0.97
Shares 53.43M
Beta 1.45
Inst. own 121%
Aug 5, 2013
Q2 2013 Insulet Corporation Earnings Release Add to calendar
Jun 12, 2013
Insulet Corporation at William Blair Growth Stock Conference
Jun 4, 2013
Insulet Corporation at Jefferies Global Healthcare Conference
May 29, 2013
Insulet Corporation at Deutsche Bank dbAccess Health Care Conference
May 15, 2013
Insulet Corporation Annual Shareholder Meeting
May 6, 2013
Q1 2013 Insulet Corporation Earnings Conference Call
May 6, 2013
Q1 2013 Insulet Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -18.59% -24.54%
Operating margin -10.82% -17.02%
EBITD margin - -11.80%
Return on average assets -17.86% -24.74%
Return on average equity -49.25% -81.74%
Employees 538 -
Carbon Disclosure Rating - -

Address

9 Oak Park Drive
BEDFORD, MA 01730
United States - Map
+1-781-4575000 (Phone)
+1-781-4575011 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the Company's handheld, wireless Personal Diabetes Manager (PDM). The OmniPod Insulin Management System is designed to provide people with insulin-dependent diabetes with a diabetes management solution which provides lifestyle and other benefits and to expand the use of continuous subcutaneous insulin infusion (CSII) therapy.

Officers and directors

Duane M. DeSisto President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Brian K. Roberts CPA Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Charles T. Liamos Chief Operating Officer, Director
Age: 53
Bio & Compensation  - Reuters
R. Anthony Diehl Esq. General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Peter Devlin Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Sally W. Crawford Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
W. Mark Lortz Director
Age: 61
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 62
Bio & Compensation  - Reuters
Steven T. Sobieski Independent Director
Age: 56
Bio & Compensation  - Reuters